查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1268946

2023-2030 年全球精准医学软件市场

Global Precision Medicine Software Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

精准医学软件市场预计到 2030 年将达到 37.064 亿美元，高于 2022 年创纪录的 15.507 亿美元，预测期内復合年增长率为 11.8%。 主要市场参与者通过产品发布、收购、合作、联合研究和业务扩展等各种市场策略占据了大部分市场份额。

例如，2023 年 3 月 1 日，飞利浦将连接其肿瘤学、病理学、放射学和心脏病学团队，创建一个完整的医疗平台，以提高临床信心并提高诊断和治疗的准确性。推出可互操作的智能成像系统和信息学解决方案。 例如，2023 年 1 月 9 日，癌症分子分析领域的领导者 Foundation Medical, Inc. 和无细胞 DNA 检测领域的全球领导者 Natera, Inc. 宣布他们将加入早期访问计划因此，设计了 FoundationOne Tracker，一种个性化的循环肿瘤 DNA (ctDNA) 监测分析。 此外，临床试验现在可以采用试验性药物试验变体。

近年来，受基因组学进步、电子健康记录 (EHR) 日益普及以及个性化医疗需求不断增长的推动，全球精准医学软件市场经历了显着增长。 随着精准医学成为主流并融入常规临床实践，预计未来几年市场将继续以显着速度增长。

基因组学的快速发展（例如 DNA 测序技术）产生了大量的基因组数据。 精准医学软件在分析和解释这些基因组数据以识别緻病基因突变、指导治疗和製定个性化治疗计划方面发挥着关键作用。

市场动态

电子健康檔案（EHR）实施进展

电子健康记录 (EHR) 的激增是医疗保健行业（包括精准医疗行业）的主要推动力。 EHR 是患者病史的数字化版本，包括医疗状况、诊断、治疗、用药和其他相关健康信息，以电子形式存储并可供授权的医疗保健专业人员访问。

EHR 的采用受到多种因素的推动，包括政府举措、监管要求、技术进步以及改善医疗保健结果的需要。 EHR 使医疗保健提供者能够快速轻鬆地访问患者的综合病史，包括对精准医疗至关重要的基因组数据。 这使医疗保健提供者能够就患者护理做出更明智的决定，制定个性化的治疗计划，并根据个人健康特征进行有针对性的干预。。

EHR 可以在不同的医疗保健提供者和设施之间无缝交换患者信息，促进更好的护理协调。 这在精准医学中尤为重要，因为患者护理可能涉及多个利益相关者，包括遗传学家、肿瘤学家、药剂师和其他专家。 EHR 可以交换基因组数据、临床数据和其他相关信息，以支持不同医疗机构的精准医疗决策。

精准医疗软件成本高

精准医疗软件的高成本是影响全球精准医疗软件市场增长的重要市场製约因素之一。 精准医学软件涉及復杂的算法和数据分析，以分析和解释大量数据，包括基因组、临床和生活方式数据，并为患者提供个性化的治疗计划。 此类高级软件解决方案的应用程序类型、实施和维护可能成本高昂，对部署和利用提出了挑战。

精密医学软件需要持续研究，以跟上基因组数据分析、数据集成和决策算法的最新进展。 投资研发以开发和更新精准医学软件可能成本高昂，尤其是对于资源有限的小型企业和组织而言。

COVID-19 影响分析

COVID-19 疫情正在加速数字技术在医疗保健领域的采用，包括远程医疗、远程监控和数字健康解决方案的使用。 这种对数字技术的日益依赖也可能推动精准医学软件的采用，该软件能够远程访问基因组数据、远程医疗护理、远程监控和为患者制定个性化治疗计划。 精准医学软件还可以帮助管理针对 COVID-19 的潜在治疗方法和疫苗的临床试验。

COVID-19 大流行扰乱了许多领域的研究，包括精准医学。 临床试验、数据收集和研究合作受到封锁、旅行限制和资源重新分配以应对大流行病的影响。

俄乌衝突分析

精准医学在很大程度上依赖于大量多样的数据集的可用性，以进行分析和决策。 衝突可能会扰乱俄罗斯和乌克兰之间的数据共享和交换，导致精准医学研究和应用对相关患者数据的访问受到限制。 衝突可能导致医疗保健专业人员（包括研究人员和临床医生）从受影响地区搬迁。 因此，研究工作可能会因精准医学领域专业知识和人才的流失而受挫。 需要注意的是，形势复杂多变，对精准医疗软件的实际影响可能因衝突的具体情况而异。

内容

第 1 章研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章定义和概述

第 3 章执行摘要

  • 按投放模式分类的摘要
  • 按应用类型分类的片段
  • 最终用户的片段
  • 区域摘要

第四章市场动态

  • 影响因素
    • 主持人
      • 电子健康记录 (EHR) 越来越受欢迎
      • 对个性化医疗的需求不断增长
    • 约束因素
      • 研发费用
      • 数据存储和计算成本
    • 机会
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 价格分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • 在 COVID-19 情景之前
    • 当前的 COVID-19 情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 结论

第七章分销模式

  • 基于云的交付模式
  • 本地交付模式

第 8 章按应用程序类型

  • 肿瘤科
  • 药物基因组学
  • 罕见病
  • 其他

第 9 章最终用户

  • 医务人员
  • 研究中心/学术机构
  • 製药和生物技术公司
  • 其他

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第11章竞争格局

  • 竞争场景
  • 市场分析/份额分析
  • 併购分析

第12章公司简介

  • Foundation Medicine Inc.（F. Hoffmann-La Roche Ltd）
    • 公司简介
    • 交付模式组合和评论
    • 财务摘要
    • 主要应用类型
  • Koninklijke Philips N.V.
  • QIAGEN
  • Hitachi Vantara LLC（Hitachi）
  • Sophia Genetics SA
  • Pieriandx, Inc.（Velsera）
  • Syapse, Inc
  • MediCardia Health
  • Lifeomic Holdings LLC
  • Fabric Genomics, Inc.

第13章 附录

简介目录
Product Code: HCIT1725

Market Overview

The precision medicine software market is expected to reach US$ 3,706.4 million in 2030, from its recorded value of US$ 1,550.7 million in 2022, growing with a CAGR of 11.8% during the forecast period. A few of the key market players such as Hitachi Vantara LLC (Hitachi, Ltd.), Koninklijke Philips N.V., Syapse, Inc., SOPHiA GENETICS, QIAGEN, Velsera, Foundation Medicine Inc. (F. Hoffmann-La Roche Ltd), 2bPrecise (AccessDx Laboratory), Pieriandx, Inc., MediCardia Health, Translational Software Inc., and Lifeomic Holdings LLC among others hold a majority of the market share through various market strategies such as product launches, acquisitions, partnerships, collaborations, and business expansions.

For instance, on March 01, 2023, Philips introduced its completely interoperable smart imaging systems and informatics solutions to connect crews in oncology, pathology, radiology, and cardiology to improve clinical conviction and promote precision in diagnosis and treatment. For instance, on January 09, 2023, the personalized circulating tumor DNA (ctDNA) monitoring assay FoundationOne Tracker was invented by Foundation Medical, Inc., a leader in molecular profiling for cancer, and Natera, Inc., a world leader in cell-free DNA testing, as part of an early access program for clinical usage. Moreover, clinical trials can now employ the test's investigational use-only variant.

The global precision medicine software market has been witnessing significant growth in recent years, driven by advancements in genomics, increasing adoption of electronic health records (EHRs), and growing demand for personalized medicine. The market is expected to continue to grow at a considerable rate in the coming years, as precision medicine becomes more mainstream and integrated into routine clinical practice.

Rapid advancements in genomics, including DNA sequencing technologies, have enabled the generation of vast amounts of genomic data. Precision medicine software plays a critical role in analyzing and interpreting this genomic data to identify disease-causing genetic mutations, guide treatment decisions, and develop personalized treatment plans.

Market Dynamics

Increasing adoption of electronic health records (EHRs)

The increasing adoption of electronic health records (EHRs) has been a significant driver in the healthcare industry, including the field of precision medicine. EHRs are digital versions of a patient's medical history, including their medical conditions, diagnoses, treatments, medications, and other relevant health information, which are stored in electronic format and can be accessed by authorized healthcare providers.

The adoption of EHRs has been driven by various factors, including government initiatives, regulatory requirements, technological advancements, and the need for improved healthcare outcomes. EHRs provide healthcare providers with quick and easy access to a patient's comprehensive medical history, including genomic data, which is crucial for precision medicine. This enables healthcare providers to make more informed decisions about patient care, develop personalized treatment plans, and tailor interventions based on an individual's unique health characteristics.

EHRs allow for a seamless exchange of patient information among different healthcare providers and facilities, facilitating better coordination of care. This is especially important in precision medicine, where multiple stakeholders, including geneticists, oncologists, pharmacists, and other specialists, may be involved in a patient's care. EHRs enable the exchange of genomic data, clinical data, and other relevant information, supporting precision medicine decision-making across different healthcare settings.

High cost of precision medicine software

The high cost of precision medicine software is one of the significant market restraints that may impact the global precision medicine software market growth. Precision medicine software involves complex algorithms and data analytics to analyze and interpret large amounts of data, including genomic data, clinical data, and lifestyle data, to provide personalized treatment plans for patients. The application type, implementation, and maintenance of such sophisticated software solutions can be costly, which may pose challenges for adoption and utilization.

Precision medicine software requires continuous research to keep up with the latest advancements in genomic data analysis, data integration, and decision-making algorithms. Investing in R&D to develop and update precision medicine software can be costly, especially for smaller companies or organizations with limited resources.

COVID-19 Impact Analysis

The COVID-19 pandemic has accelerated the adoption of digital technologies in healthcare, including the use of telemedicine, remote monitoring, and digital health solutions. This increased reliance on digital health technologies may also drive the adoption of precision medicine software, which can provide remote access to genomic data, facilitate teleconsultations, and enable remote monitoring and personalized treatment plans for patients. Precision medicine software can also aid in the management of clinical trials for potential treatments and vaccines for COVID-19.

The COVID-19 pandemic has disrupted research in many areas, including precision medicine. Clinical trials, data collection, and research collaborations have been impacted by lockdowns, travel restrictions, and resource reallocation to address the pandemic.

Russia-Ukraine Conflict Analysis

Precision medicine relies heavily on the availability of large and diverse datasets for analysis and decision-making. The conflict may disrupt data sharing and exchange between Russia and Ukraine, leading to limited access to relevant patient data for precision medicine research and applications. Conflict can lead to the displacement of healthcare professionals, including researchers and clinicians, from the affected region. This can result in a loss of expertise and talent in the field of precision medicine, leading to potential setbacks in research efforts. It's important to note that the situation is complex and evolving, and the actual impact on precision medicine software may vary depending on the specific circumstances of the conflict.

Segment Analysis

The global precision medicine software market is segmented based on delivery mode, application type, end user, and region.

Cloud-based segment drives the market growth

The market value for cloud-based segment is likely to reach US$ 2,436.6 million in 2030, from its recorded value of US$ 1,011.8 million in 2022, growing with a CAGR of 11.9% during the forecast period (2023 to 2030).

Cloud-based deployment means renting an internet space from a third party and storing the data on remote servers. This solution is convenient as it has no upfront costs and requires no additional staff to maintain hardware. Cloud deployment is scalable and flexible according to the budget and usage, eases the burden on IT staff, and easier to perform regular backups.

For instance, Synapse Raydar is a complete real-world data platform created by combining technology, deep clinical understanding, regulatory experience, and rigorous quality control. Raydar converts clinically complicated, highly contextual oncology data into actionable insights.

Raydar's patented capabilities illuminate the entire patient journey via Raydar Interoperability, Raydar Knowledge Management Services, Raydar AI, and Raydar Algo. Similarly, 2bPrecise technology, which is cloud-based, absorbs molecular data from laboratories and clinical information from EHRs, synthesizing them into a clinical-genomic ontology and giving precision medicine insights to doctors inside their familiar workflow across any EHR. Furthermore, the solution is designed to interact with changing information sources and care recommendations. When combined with the rest of the patient information, this actionable data set contributes to improved diagnosis and early treatment.

Geographical Analysis

The strong presence of major players and increased awareness about the use of eco-friendly delivery modes

The North American precision medicine software market was valued at US$ 667.2 million in 2022 and is likely to reach US$ 1,611.3 million by 2030, growing at a CAGR of 12.0% during 2023-2030.

North America accounted for the highest market share of 43.0% in 2022, which will increase to 43.37% in 2030. The presence of a large number of pharmaceutical companies, growing R&D expenditure, rising patient preference for precision medicine, collaborative agreements among manufacturers, and surging cancer patients, new product launches, and technological advancements are driving the growth of the market in the region.

For instance, according to National Cancer Institute, approximately 1,806,590 new cases were analyzed with cancer, which led to 606,520 deaths in 2020. Moreover, the American Cancer Society identified 1.9 million cancer cases in 2021, and over 608,570 deaths were cancer-related. Similarly, CDC assessed that annual new cancer cases will be 29.5 million by 2040.

Moreover, the presence of key market players such as Syapse, Inc, 2bprecise, LLC, Fabric Genomics, Inc., Foundation Medicine, Inc., Velsera, Translational Software Inc., LifeOmic Holdings LLC, and Koninklijke Philips N.V. among others holding most of the precision medicine software market is expected to ensure the growth of North American precision medicine software market at a high CAGR throughout the forecast period.

Competitive Landscape

The precision medicine software market is highly competitive with the presence of a large number of existing major players and small vendors. Some of the major players in the global precision medicine software market include Hitachi Vantara LLC (Hitachi, Ltd.), Koninklijke Philips N.V., Syapse, Inc., SOPHiA GENETICS, QIAGEN, Velsera, Foundation Medicine Inc. (F. Hoffmann-La Roche Ltd), 2bPrecise (AccessDx Laboratory), Pieriandx, Inc., MediCardia Health, Translational Software Inc., and Lifeomic Holdings LLC among others.

Why Purchase the Report?

  • To visualize the global precision medicine software market segmentation based on delivery mode, application type, end user, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-Application Type.
  • Excel data sheet with numerous data points of precision medicine software market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Delivery Mode mapping available as Excel consisting of key Delivery Modes of all the major players.

The global precision medicine software market report would provide approximately 54 tables, 46 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Delivery Mode
  • 3.2. Snippet by Application Type
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Adoption of Electronic Health Records (EHRs)
      • 4.1.1.2. Growing Demand for Personalized Medicine
    • 4.1.2. Restraints
      • 4.1.2.1. Research and Development (R&D) Costs
      • 4.1.2.2. Data Storage and Computing Costs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Delivery Mode

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 7.1.2. Market Attractiveness Index, By Delivery Mode
  • 7.2. Cloud-Based Delivery Mode*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. On-Premise Delivery Mode

8. By Application Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Type
    • 8.1.2. Market Attractiveness Index, By Application Type
  • 8.2. Oncology*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Pharmacogenomics
    • 8.2.4. Rare Diseases
    • 8.2.5. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Health Care Providers*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 9.2.3. Research Centers and Academic Institutes
    • 9.2.4. Pharmaceutical & Biotechnology Companies
    • 9.2.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Foundation Medicine Inc. (F. Hoffmann-La Roche Ltd) *
    • 12.1.1. Company Overview
    • 12.1.2. Delivery Mode Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Application Types
  • 12.2. Koninklijke Philips N.V.
  • 12.3. QIAGEN
  • 12.4. Hitachi Vantara LLC (Hitachi)
  • 12.5. Sophia Genetics SA
  • 12.6. Pieriandx, Inc. (Velsera)
  • 12.7. Syapse, Inc
  • 12.8. MediCardia Health
  • 12.9. Lifeomic Holdings LLC
  • 12.10. Fabric Genomics, Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us